Actively Recruiting
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Led by Sichuan University · Updated on 2026-02-09
202
Participants Needed
1
Research Sites
205 weeks
Total Duration
On this page
Sponsors
S
Sichuan University
Lead Sponsor
S
Shanghai Shengdi Pharmaceutical Co., Ltd
Collaborating Sponsor
AI-Summary
What this Trial Is About
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined with Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
CONDITIONS
Official Title
Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants aged 18 to 75 years
- ECOG Performance Status (PS) score of 0-1
- Expected survival duration of no less than 8 weeks
- Histologically or cytologically confirmed extensive small cell lung cancer (according to the VALG staging system)
- No prior systemic therapy or radical radiotherapy for extensive SCLC
You will not qualify if you...
- Mixed small cell lung cancer and non-small cell lung cancer tissue types
- Major surgery within 28 days before study drug administration or planned during the study
- Receipt of live attenuated vaccines within 28 days before first dose or planned during the study
- Participation in another clinical trial with experimental agents within 28 days before dosing
- Previous chest radiotherapy or planned intensive chest radiotherapy before systemic therapy
- Prior T-cell co-stimulation or immune checkpoint therapies
- History of allogeneic organ or hematopoietic stem cell transplantation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital of Sichuan University
Sichuan, China
Actively Recruiting
Research Team
Y
You Lu
CONTACT
Z
Zhuoran Yao, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here